Gurnari, Carmelo http://orcid.org/0000-0001-6829-5544
Xie, Zhuoer
Zeidan, Amer M. http://orcid.org/0000-0001-7017-8160
Funding for this research was provided by:
Edward P. Evans Foundation
Article History
Received: 28 September 2022
Accepted: 14 November 2022
First Online: 27 December 2022
Declarations
:
: Amer M. Zeidan is a Leukemia and Lymphoma Society Scholar in Clinical Research, who received research funding (institutional) from Celgene/BMS, Abbvie, Astex, Pfizer, Medimmune/AstraZeneca, Boehringer-Ingelheim, Cardiff oncology, Incyte, Takeda, Novartis, Aprea, and ADC Therapeutics; participated in advisory boards, and/or had a consultancy with and received honoraria from AbbVie, Otsuka, Pfizer, Celgene/BMS, Jazz, Incyte, Agios, Boehringer-Ingelheim, Novartis, Acceleron, Astellas, Daiichi Sankyo, Cardinal Health, Taiho, Seattle Genetics, BeyondSpring, Cardiff Oncology, Takeda, Ionis, Amgen, Janssen, Genentech, Epizyme, Syndax, Gilead, Kura, Chiesi, ALX Oncology, BioCryst, Notable, Orum, Mendus, Foran, Syros, and Tyme; served on clinical trial committees for Novartis, Abbvie, Gilead, BioCryst, Abbvie, ALX Oncology, Geron and Celgene/BMS. The other authors declare no competing financial interests.
: Not applicable.
: All authors approved the final version of this manuscript.